🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Alpha Tau Medical that the #FDA has approved an Investigational Device Exemption (IDE) application to initiate a pilot study for the treatment of patients with recurrent glioblastoma (#GBM) using the Alpha DaRT technology alphatau.com/single-post/al…

The upcoming Digestive Disease Week, the premier conference for those working in #Gastroenterology, hepatology, GI endoscopy and gastrointestinalsurgery, will be held in San Diego (May 3-6) and is a perfect stage to showcase our inner organs treatment capabilities. linkedin.com/posts/alphatau…

Being a company currently focused on research, this is another sign of our efforts to put patient well-being at the center: linkedin.com/posts/alphatau…

🕯️ Remembering the victims of the Holocaust. Never forget, never again. #YomHaShoah #HolocaustRemembranceDay

Alpha Tau Medical Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharma alphatau.com/single-post/al…

Transforming Pancreatic Cancer Care with Precision Oncology at #DDW2025. Alpha TAU will present the endoscopic application of EUS-guided intratumoral radium-224 therapy - a groundbreaking innovation designed to enhance survival and quality of life. Visit us at Booth #5416

Alpha Tau Medical announced that CFO Raphi Levy will presentation in the following #investorconferences in May 2025. alphatau.com/single-post/al…

Alpha Tau Medical reported first quarter 2025 financial results and provided a corporate update. For the full announcement, please read: alphatau.com/single-post/al…

🌞 May is #SkinCancerAwareness Month! Early detection is key, but new treatments are also changing the game. We’re innovating with #AlphaDaRT®, designed as a single-session, targeted therapy for skin tumors, currently available only in clinical trials.

#AlphaTau is redefining the fight against #solidtumors. A Few Q1 2025 Highlights: ✔️ $36.9M capital raise fueling global expansion ✔️ 90%+ disease control in Jan interim readout of pancreatic cancer trials For the full picture, visit loom.ly/wkosSts

Alpha Tau heads to #IAOO2025 📍Liverpool | July 17–18 Presenting results from our Alpha DaRT® + pembrolizumab trial in recurrent head & neck cancer. One-time, intratumoral treatment. 📍Booth 19 | Let’s connect. #AlphaDaRT #Radium224 #OncologyInnovation

A 96-year-old with Stage IV SCC, ECOG 3, cardiac history, and dementia - not a candidate for surgery or combo therapy - achieved NED at 25 months after one Alpha DaRT® insertion + later anti-PD1. ➡️ Intratumoral first. Systemic second. linkedin.com/posts/alphatau…

🎙️ Prof. Aron Popovtzer (Hadassah Medical Center) explains in an interview on Alpha Tau Medical’s Website how Alpha DaRT®, currently available only in clinical trials, is changing the way we think about immune activation in head & neck cancer: alphatau.com/single-post/co…\

Most still blast radiation at tumors. What if we fight from within? Alpha DaRT® delivers ultra-high dose inside the tumor - in 1 session, sparing healthy tissue.🎙️Prof. Popovtzer at #IAOO2025 📅 July 18 | 14:00 #AlphaDaRT #Radium224 #OralCancer